Advertisement

Neurotherapeutics

, Volume 7, Issue 3, pp 283–292 | Cite as

Immune dysfunction in autism: A pathway to treatment

  • Milo Careaga
  • Judy Van de Water
  • Paul AshwoodEmail author
Review Article

Summary

Autism is a complex and clinically heterogeneous disorder with a spectrum of symptoms. Clinicians, schools, and service agencies worldwide have reported a dramatic increase in the number of children identified with autism. Despite expanding research, the etiology and underlying biological processes of autism remain poorly understood, and the relative contribution from genetic, epigenetic, and environmental factors remains unclear. Although autism affects primarily brain function (especially affect, social functioning, and cognition), it is unknown to what extent other organs and systems are disrupted. Published findings have identified widespread changes in the immune systems of children with autism, at both systemic and cellular levels. Brain specimens from autism subjects exhibit signs of active, ongoing inflammation, as well as alterations in gene pathways associated with immune signaling and immune function. Moreover, many genetic studies have indicated a link between autism and genes that are relevant to both the nervous system and the immune system. Alterations in these pathways can affect function in both systems. Together, these reports suggest that autism may in fact be a systemic disorder with connections to abnormal immune responses. Such immune system dysfunction may represent novel targets for treatment. A better understanding of the involvement of the immune response in autism, and of how early brain development is altered, may have important therapeutic implications.

Key words

Autism immune system autoimmunity signaling pathways 

References

  1. 1.
    Money J, Bobrow NA, Clarke FC. Autism and autoimmune disease: a family study. J Autism Child Schizophr 1971;1: 146–160.PubMedGoogle Scholar
  2. 2.
    Atladóttir HO, Pedersen MG, Thorsen P, et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 2009;124: 687–694.PubMedGoogle Scholar
  3. 3.
    Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med 2005;159: 151–157.PubMedGoogle Scholar
  4. 4.
    Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009;33: 197–207.PubMedGoogle Scholar
  5. 5.
    Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol 1999;14: 388–394.PubMedGoogle Scholar
  6. 6.
    Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics 2003;112: e420.PubMedGoogle Scholar
  7. 7.
    Micali N, Chakrabarti S, Fombonne E. The broad autism phenotype: findings from an epidemiological survey. Autism 2004;8: 21–37.PubMedGoogle Scholar
  8. 8.
    Molloy CA, Morrow AL, Meinzen-Derr J, et al. Familial autoimmune thyroid disease as a risk factor for regression in children with autism spectrum disorder: a CPEA Study. J Autism Dev Disord 2006;36: 317–324.PubMedGoogle Scholar
  9. 9.
    Mouridsen SE, Rich B, Isager T, Nedergaard NJ. Autoimmune diseases in parents of children with infantile autism: a case-control study. Dev Med Child Neurol 2007;49: 429–432.PubMedGoogle Scholar
  10. 10.
    Valicenti-McDermott MD, McVicar K, Cohen HJ, Wershil BK, Shinnar S. Gastrointestinal symptoms in children with an autism spectrum disorder and language regression. Pediatr Neurol 2008;39: 392–398.PubMedGoogle Scholar
  11. 11.
    Tincani A, Rebaioli CB, Frassi M, et al.; Pregnancy Study Group of Italian Society of Rheumatology. Pregnancy and autoimmunity: maternal treatment and maternal disease influence on pregnancy outcome. Autoimmun Rev 2005;4: 423–428.PubMedGoogle Scholar
  12. 12.
    Croen LA, Braunschweig D, Haapanen L, et al. Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study. Biol Psychiatry 2008;64: 583–588.PubMedGoogle Scholar
  13. 13.
    Warren RP, Cole P, Odell JD, et al. Detection of maternal antibodies in infantile autism. J Am Acad Child Adolesc Psychiatry 1990;29: 873–877.PubMedGoogle Scholar
  14. 14.
    Dalton P, Deacon R, Blamire A, et al. Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol 2003;53: 533–537.PubMedGoogle Scholar
  15. 15.
    Zimmerman AW, Connors SL, Matteson KJ, et al. Maternal antibrain antibodies in autism. Brain Behav Immun 2007;21: 351–357.PubMedGoogle Scholar
  16. 16.
    Braunschweig D, Ashwood P, Krakowiak P, et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology 2008;29: 226–231.PubMedGoogle Scholar
  17. 17.
    Singer HS, Morris CM, Gause CD, Gillin PK, Crawford S, Zimmerman AW. Antibodies against fetal brain in sera of mothers with autistic children. J Neuroimmunol 2008;194: 165–172.PubMedGoogle Scholar
  18. 18.
    Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun 2008;22: 806–816.PubMedGoogle Scholar
  19. 19.
    Singer HS, Morris C, Gause C, Pollard M, Zimmerman AW, Pletnikov M. Prenatal exposure to antibodies from mothers of children with autism produces neurobehavioral alterations: a pregnant dam mouse model. J Neuroimmunol 2009;211: 39–48.PubMedGoogle Scholar
  20. 20.
    Silva SC, Correia C, Fesel C, et al. Autoantibody repertoires to brain tissue in autism nuclear families. J Neuroimmunol 2004;152: 176–182.PubMedGoogle Scholar
  21. 21.
    McAllister DL, Kaplan BJ, Edworthy SM, et al. The influence of systemic lupus erythematosus on fetal development: cognitive, behavioral, and health trends. J Int Neuropsychol Soc 1997;3: 370–376.PubMedGoogle Scholar
  22. 22.
    Neri F, Chimini L, Bonomi F, et al. Neuropsychological development of children born to patients with systemic lupus erythematosus. Lupus 2004;13: 805–811.PubMedGoogle Scholar
  23. 23.
    Tincani A, Danieli E, Nuzzo M, et al.; Pregancy Study Group of Italian Society of Rheumatology. Impact of in utero environment on the offspring of lupus patients. Lupus 2006;15: 801–807.PubMedGoogle Scholar
  24. 24.
    Lee LA. The clinical spectrum of neonatal lupus. Arch Dermatol Res 2009;301: 107–110.PubMedGoogle Scholar
  25. 25.
    Lee JY, Huerta PT, Zhang J, et al. Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med 2009;15: 91–96.PubMedGoogle Scholar
  26. 26.
    Klauck SM, Poustka A. Animal models of autism. Drug Discov Today Dis Models 2006;3: 313–318.Google Scholar
  27. 27.
    Enstrom AM, Van de Water JA, Ashwood P. Autoimmunity in autism. Curr Opin Investig Drugs 2009;10: 463–473.PubMedGoogle Scholar
  28. 28.
    Fernando MM, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008;4: e1000024.PubMedGoogle Scholar
  29. 29.
    Stubbs EG, Magenis RE. HLA and autism. J Autism Dev Disord 1980;10: 15–19.PubMedGoogle Scholar
  30. 30.
    Stubbs EG, Ritvo ER, Mason-Brothers A. Autism and shared parental HLA antigens. J Am Acad Child Psychiatry 1985;24: 182–185.PubMedGoogle Scholar
  31. 31.
    Spence MA, Ritvo ER, Marazita ML, Funderburk SJ, Sparkes RS, Freeman BJ. Gene mapping studies with the syndrome of autism. Behav Genet 1985;15: 1–13.PubMedGoogle Scholar
  32. 32.
    Warren RP, Singh VK, Cole P, et al. Possible association of the extended MHC haplotype B44-SC30-DR4 with autism. Immunogenetics 1992;36: 203–207.PubMedGoogle Scholar
  33. 33.
    Daniels WW, Warren RP, Odell JD, et al. Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism. Neuropsychobiology 1995;32: 120–123.PubMedGoogle Scholar
  34. 34.
    Warren RP, Singh VK, Averett RE, et al. Immunogenetic studies in autism and related disorders. Mol Chem Neuropathol 1996;28: 77–81.PubMedGoogle Scholar
  35. 35.
    Rogers T, Kalaydjieva L, Hallmayer J, et al. Exclusion of linkage to the HLA region in ninety multiplex sibships with autism. J Autism Dev Disord 1999;29: 195–201.PubMedGoogle Scholar
  36. 36.
    Tones AR, Maciulis A, Stubbs EG, Cutler A, Odell D. The transmission disequilibrium test suggests that HLA-DR4 and DR13 are linked to autism spectrum disorder. Hum Immunol 2002;63: 311–316.Google Scholar
  37. 37.
    Lee LC, Zachary AA, Leffell MS, et al. HLA-DR4 in families with autism. Pediatr Neurol 2006;35: 303–307.PubMedGoogle Scholar
  38. 38.
    Guerini FR, Bolognesi E, Manca S, et al. Family-based transmission analysis of HLA genetic markers in Sardinian children with autistic spectrum disorders. Hum Immunol 2009;70: 184–190.PubMedGoogle Scholar
  39. 39.
    Johnson WG, Buyske S, Mars AE, et al. HLA-DR4 as a risk allele for autism acting in mothers of probands possibly during pregnancy. Arch Pediatr Adolesc Med 2009;163: 542–546.PubMedGoogle Scholar
  40. 40.
    Wan-en RP, Burger RA, Odell D, Tones AR, Warren WL. Decreased plasma concentrations of the C4B complement protein in autism. Arch Pediatr Adolesc Med 1994;148: 180–183.Google Scholar
  41. 41.
    Wan-en RP, Yonk J, Burger RW, Odell D, Wan-en WL. DR-positive T cells in autism: association with decreased plasma levels of the complement C4B protein. Neuropsychobiology 1995;31: 53–57.Google Scholar
  42. 42.
    Odell D, Maciulis A, Cutler A, et al. Confirmation of the association of the C4B null allele in autism. Hum Immunol 2005;66: 140–145.PubMedGoogle Scholar
  43. 43.
    Grigorenko EL, Han SS, Yrigollen CM, et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 2008;122: e438-e445.PubMedGoogle Scholar
  44. 44.
    Correll PH, Morrison AC, Lutz MA. Receptor tyrosine kinases and the regulation of macrophage activation. J Leukoc Biol 2004;75: 731–737.PubMedGoogle Scholar
  45. 45.
    Lintas C, Sacco R, Garbett K, et al. Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression. Mol Psychiatry 2009;14: 705–718.PubMedGoogle Scholar
  46. 46.
    Herman GE, Butter E, Emile B, Pastore M, Prior TW, Sommer A. Increasing knowledge of PTEN germline mutations: two additional patients with autism and macrocephaly. Am J Med Genet A 2007;143: 589–593.PubMedGoogle Scholar
  47. 47.
    Serajee FJ, Zhong H, Mahbubul Huq AH. Association of Reelin gene polymorphisms with autism. Genomics 2006;87: 75–83.PubMedGoogle Scholar
  48. 48.
    Skaar DA, Shao Y, Haines JL, et al. Analysis of the RELN gene as a genetic risk factor for autism. Mol Psychiatry 2005;10: 563–571.PubMedGoogle Scholar
  49. 49.
    Zhang H, Liu X, Zhang C, et al. Reelin gene alleles and susceptibility to autism spectrum disorders. Mol Psychiatry 2002;7: 1012–1017.PubMedGoogle Scholar
  50. 50.
    Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism [Erratum in: Ann Neurol 2005;57:304]. Ann Neurol 2005;57: 67–81.PubMedGoogle Scholar
  51. 51.
    Ashwood P, Anthony A, Torrente F, Wakefield AJ. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J Clin Immunol 2004;24: 664–673.PubMedGoogle Scholar
  52. 52.
    Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol 2006;173: 126–134.PubMedGoogle Scholar
  53. 53.
    Singh VK, Wan-en RP, Odell JD, Cole P. Changes of soluble interleukin-2, interleukin-2 receptor, T8 antigen, and interleukin-1 in the serum of autistic children. Clin Immunol Immunopathol 1991;61: 448–455.PubMedGoogle Scholar
  54. 54.
    Singh VK. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol 1996;66: 143–145.PubMedGoogle Scholar
  55. 55.
    Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001;120: 170–179.PubMedGoogle Scholar
  56. 56.
    Ashwood P, Enstrom A, Krakowiak P, et al. Decreased transforming growth factor betal in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 2008;204: 149–153.PubMedGoogle Scholar
  57. 57.
    Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology 2002;46: 76–84.PubMedGoogle Scholar
  58. 58.
    Ashwood P, Anthony A, Pellicer AA, Torrente F, Walker-Smith JA, Wakefield AJ. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol 2003;23: 504–517.PubMedGoogle Scholar
  59. 59.
    Horvath K, Perman JA. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep 2002;4: 251–258.PubMedGoogle Scholar
  60. 60.
    Genuis SJ, Bouchard TP. Celiac disease presenting as autism. J Child Neurol 2010;25: 114–119.PubMedGoogle Scholar
  61. 61.
    Wills S, Cabanlit M, Bennett J, Ashwood P, Amaral D, Van de Water J. Autoantibodies in autism spectrum disorders (ASD). Ann N Y Acad Sci 2007;1107: 79–91.PubMedGoogle Scholar
  62. 62.
    Todd RD, Ciaranello RD. Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc Natl Acad Sci U S A 1985;82: 612–616.PubMedGoogle Scholar
  63. 63.
    Singh VK, Wan-en RP, Odell JD, Wan-en WL, Cole P. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immun 1993;7: 97–103.PubMedGoogle Scholar
  64. 64.
    Singh VK, Warren R, Averett R, Ghaziuddin M. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr Neurol 1997;17: 88–90.PubMedGoogle Scholar
  65. 65.
    Singh VK, Lin SX, Yang VC. Serological association of measles virus and human herpesvirus-6 with brain autoantibodies in autism. Clin Immunol Immunopathol 1998;89: 105–108.PubMedGoogle Scholar
  66. 66.
    Evers M, Cunningham-Rundles C, Hollander E. Heat shock protein 90 antibodies in autism. Mol Psychiatry 2002;7 Suppl 2: S26-S28.PubMedGoogle Scholar
  67. 67.
    Vojdani A, O’Bryan T, Green JA, et al. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nute Neurosci 2004;7: 151–161.Google Scholar
  68. 68.
    Singh VK, Rivas WH. Prevalence of serum antibodies to caudate nucleus in autistic children. Neurosci Lett 2004;355: 53–56.PubMedGoogle Scholar
  69. 69.
    Singh VK, Rivas WH. Detection of antinuclear and antilaminin antibodies in autistic children who received thimerosal-containing vaccines. J Biomed Sci 2004;11: 607–610.PubMedGoogle Scholar
  70. 70.
    Connolly AM, Chez M, Streif EM, et al. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatry 2006;59: 354–363.PubMedGoogle Scholar
  71. 71.
    Singer HS, Morris CM, Williams PN, Yoon DY, Hong JJ, Zimmerman AW. Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol 2006;178: 149–155.PubMedGoogle Scholar
  72. 72.
    Libbey JE, Coon HH, Kirkman NJ, et al. Are there enhanced MBP autoantibodies in autism? J Autism Dev Disord 2008;38: 324–332.PubMedGoogle Scholar
  73. 73.
    Kirkman NJ, Libbey JE, Sweeten TL, et al. How relevant are GFAP autoantibodies in autism and Tourette Syndrome? J Autism Dev Disord 2008;38: 333–341.PubMedGoogle Scholar
  74. 74.
    Wills S, Cabanlit M, Bennett J, Ashwood P, Amaral DG, Van de Water J. Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders. Brain Behav Immun 2009;23: 64–74.PubMedGoogle Scholar
  75. 75.
    Torrente F, Ashwood P, Day R, et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry 2002;7: 375–382, 334.PubMedGoogle Scholar
  76. 76.
    Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124: 471–484.PubMedGoogle Scholar
  77. 77.
    Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord 2007;37: 738–747.PubMedGoogle Scholar
  78. 78.
    Wiznitzer M. Autism and tuberous sclerosis. J Child Neurol 2004;19: 675–679.PubMedGoogle Scholar
  79. 79.
    Williams PG, Hersh JH. Brief report: the association of neurofibromatosis type 1 and autism. J Autism Dev Disord 1998;28: 567–571.PubMedGoogle Scholar
  80. 80.
    Cuscó I, Medrano A, Gener B, et al. Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorder. Hum Mol Genet 2009;18: 1795–1804.PubMedGoogle Scholar
  81. 81.
    Stubbs EG. Autistic children exhibit undetectable hemagglutination-inhibition antibody titers despite previous rubella vaccination. J Autism Child Schizophr 1976;6: 269–274.PubMedGoogle Scholar
  82. 82.
    Warren RP, Margaretten NC, Pace NC, Foster A. Immune abnormalities in patients with autism. J Autism Dev Disord 1986;16: 189–197.PubMedGoogle Scholar
  83. 83.
    Murch SH, Fertleman CR, Rodrigues C, et al. Autoimmune enteropathy with distinct mucosal features in T-cell activation deficiency: the contribution of T cells to the mucosal lesion. J Pediatr Gastroenterol Nute 1999;28: 393–399.Google Scholar
  84. 84.
    Mondino A, Mueller DL. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol 2007;19: 162–172.PubMedGoogle Scholar
  85. 85.
    Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002;9: 99–100.PubMedGoogle Scholar
  86. 86.
    Engstrom HA, Ohlson S, Stubbs EG, et al. Decreased expression of CD95 (FAS/APO-1) on CD4+ T-lymphocytes from participants with autism. J Dev Phys Disabil 2003;15: 155–163.Google Scholar
  87. 87.
    Fatemi SH, Stary JM, Halt AR, Realmuto GR. Dysregulation of reelin and Bcl-2 proteins in autistic cerebellum. J Autism Dev Disord 2001;31: 529–535.PubMedGoogle Scholar
  88. 88.
    Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008;105: 7797–7802.PubMedGoogle Scholar
  89. 89.
    Wu T, Mohan C. The AKT axis as a therapeutic target in autoimmune diseases. Endocr Metab Immune Disord Drug Targets 2009;9: 145–150.PubMedGoogle Scholar
  90. 90.
    Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology 2005;51: 77–85.PubMedGoogle Scholar
  91. 91.
    Weichhart T, Costantino G, Poglitsch M, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008;29: 565–577.PubMedGoogle Scholar
  92. 92.
    Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol 2007;17: 434–447.PubMedGoogle Scholar
  93. 93.
    Volkmar FR, Pauls D. Autism [Erratum in: Lancet 2004;363: 250]. Lancet 2003;362: 1133–1141.PubMedGoogle Scholar
  94. 94.
    Kemper TL, Bauman ML. Neuropathology of infantile autism. Mol Psychiatry 2002;7 Suppl 2: S12-S13.PubMedGoogle Scholar
  95. 95.
    Courchesne E, Pierce K. Brain overgrowth in autism during a critical time in development: implications for frontal pyramidal neuron and intemeuron development and connectivity. Int J Dev Neurosci 2005;23: 153–170.PubMedGoogle Scholar
  96. 96.
    Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006;27: 254–289.PubMedGoogle Scholar
  97. 97.
    Anderson GM, Home WC, Chatterjee D, Cohen DJ. The hyperserotonemia of autism. Ann N Y Acad Sci 1990;600: 331–340; discussion 341–332.PubMedGoogle Scholar
  98. 98.
    Rolf LH, Haarmann FY, Grotemeyer KH, Kehrer H. Serotonin and amino acid content in platelets of autistic children. Acta Psychiatr Scand 1993;87: 312–316.PubMedGoogle Scholar
  99. 99.
    Singh VK, Singh EA, Warren RP. Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol Psychiatry 1997;41: 753–755.PubMedGoogle Scholar
  100. 100.
    McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Rice LH. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry 1996;53: 993–1000.PubMedGoogle Scholar
  101. 101.
    Dunn AJ, Wang J, Ando T. Effects of cytokines on cerebral neurotransmission: comparison with the effects of stress. Adv Exp Med Biol 1999;461: 117–127.PubMedGoogle Scholar
  102. 102.
    Wirleitner B, Neurauter G, Schröcksnadel K, Frick B, Fuchs D. Interferon-γ-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003;10: 1581–1591.PubMedGoogle Scholar
  103. 103.
    Bjurstöm H, Wang J, Ericsson I, et al. GABA, a natural immunomodulator of T lymphocytes. J Neuroimmunol 2008;205: 44–104.PubMedGoogle Scholar
  104. 104.
    Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol 2008;8: 460–471.PubMedGoogle Scholar
  105. 105.
    Pacheco R, Gallart T, Lluis C, Franco R. Role of glutamate on T-cell mediated immunity. J Neuroimmunol 2007;185: 9–19.PubMedGoogle Scholar
  106. 106.
    Pacheco R, Ciruela F, Casadó V, et al. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J Biol Chem 2004;279: 33352–33358.PubMedGoogle Scholar
  107. 107.
    Sarchielli P, Di Filippo M, Candeliere A, et al. Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. J Neuroimmunol 2007;188: 146–158.PubMedGoogle Scholar
  108. 108.
    Pacheco R, Oliva H, Martinez-Navio JM, et al. Glutamate released by dendritic cells as a novel modulator of T cell activation. J Immunol 2006;177: 6695–6704.PubMedGoogle Scholar
  109. 109.
    Alam S, Laughton DL, Walding A, Wolstenholme AJ. Human peripheral blood mononuclear cells express GABAA receptor subunits. Mol Immunol 2006;43: 1432–1442.PubMedGoogle Scholar
  110. 110.
    Lubick K, Radke M, Jutila M. Securinine, a GABAA receptor antagonist, enhances macrophage clearance of phase II C. burnetii: comparison with TLR agonists [Erratum in: J Leukoc Biol 2008;83:1068]. J Leukoc Biol 2007;82: 1062–1069.PubMedGoogle Scholar
  111. 111.
    Levite M, Ganor Y. Autoantibodies to glutamate receptors can damage the brain in epilepsy, systemic lupus erythematosus and encephalitis. Expert Rev Neurother 2008;8: 1141–1160.PubMedGoogle Scholar
  112. 112.
    Volkmar FR, Nelson DS. Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry 1990;29: 127–129.PubMedGoogle Scholar
  113. 113.
    Raju R, Rakocevic G, Chen Z, et al. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 2006;129: 3270–3276.PubMedGoogle Scholar
  114. 114.
    Ghaziuddin M, Butler E. Clumsiness in autism and Asperger syndrome: a further report. J Intellect Disabil Res 1998;42 (Pt 1): 43–48.PubMedGoogle Scholar
  115. 115.
    Levy SE, Mandell DS, Merhar S, Ittenbach RF, Pinto-Martin JA. Use of complementary and alternative medicine among children recently diagnosed with autistic spectrum disorder. J Dev Behav Pediatr 2003;24: 418–423.PubMedGoogle Scholar
  116. 116.
    Hanson E, Kalish L, Bunce E, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord 2007;37: 628–636.PubMedGoogle Scholar
  117. 117.
    Harrington JW, Rosen L, Garnecho A, Patrick PA. Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice. J Dev Behav Pediatr 2006;27: S156-S161.PubMedGoogle Scholar
  118. 118.
    Wong HH, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord 2006;36: 901–909.PubMedGoogle Scholar
  119. 119.
    Golnik A, Ireland M. complementary alternative medicine for children with autism: a physician survey. J Autism Dev Disord 2009;39: 996–1005.PubMedGoogle Scholar
  120. 120.
    Geier MR, Geier DA. The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses 2005;64: 946–954.PubMedGoogle Scholar
  121. 121.
    Buitelaar JK, van Engeland H, van Ree JM, de Wied D. Behavioral effects of Org 2766, a synthetic analog of the adrenocorticotrophic hormone (4–9), in 14 outpatient autistic children. J Autism Dev Disord 1990;20: 467–478.PubMedGoogle Scholar
  122. 122.
    Bradstreet JJ, Smith S, Granpeesheh D, El-Dahr JM, Rossignol D. Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders. Med Hypotheses 2007;68: 979–987.PubMedGoogle Scholar
  123. 123.
    Matarazzo EB. Treatment of late onset autism as a consequence of probable autoimmune processes related to chronic bacterial infection. World J Biol Psychiatry 2002;3: 162–166.PubMedGoogle Scholar
  124. 124.
    Shenoy S, Arnold S, Chatila T. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr 2000;136: 682–687.PubMedGoogle Scholar
  125. 125.
    Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997;126: 721–730.PubMedGoogle Scholar
  126. 126.
    Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol 1998;13: 79–82.PubMedGoogle Scholar
  127. 127.
    Gupta S. Treatment of children with autism with intravenous immunoglobulin. J Child Neurol 1999;14: 203–205.PubMedGoogle Scholar
  128. 128.
    Sandler RH, Finegold SM, Bolte ER, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000;15: 429–435.PubMedGoogle Scholar
  129. 129.
    Cannell JJ. Autism and vitamin D. Med Hypotheses 2008;70: 750–759.PubMedGoogle Scholar
  130. 130.
    Sandler A. Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev 2005;11: 164–170.PubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Milo Careaga
    • 1
    • 2
  • Judy Van de Water
    • 3
  • Paul Ashwood
    • 1
    • 2
    Email author
  1. 1.Department of Medical Microbiology and ImmunologyUniversity of California at DavisSacramento
  2. 2.M.I.N.D. InstituteUniversity of California at DavisSacramento
  3. 3.Division of Rheumatology, Allergy and Clinical ImmunologyUniversity of California at DavisSacramento

Personalised recommendations